Taking after the Tigers

Field, Alan M.
February 2006
Journal of Commerce (1542-3867);2/13/2006, Vol. 7 Issue 7, p16
This article provides information on a new research consortium called the African Biotherapeutics Institute which aims to develop the vast potential of Africa for biodiversity-based, value-added products, including pharmaceuticals and nutritional products. The consortium will bring together several African universities. The goals of the new consortium are noted.


Related Articles

  • Hired Education. Washburn, Jennifer // American Prospect;Feb2005, Vol. 16 Issue 2, p29 

    Discusses the increasing number of universities in the U.S. that look and behave like business enterprises in efforts to become research branches of private industry, as of February 2005. Factors that led to the redefinition of the mission of universities; Significance of publicly funded...

  • Crunch time for pharma. Martin, John // New Scientist;10/10/2009, Vol. 204 Issue 2729, p24 

    The author reflects on the implications of financial crises for pharmaceutical research. He says that while big pharmaceutical companies have much money, universities are being starved of resources and research funding has decreased. He asserts that the tax system could at least encourage...

  • Consortia and commodities.  // Nature Biotechnology;Jul2010, Vol. 28 Issue 7, p629 

    The author comments on the rise of open source drug research and development (R&D) in consortia involving pharmaceutical companies. According to the author, pharmaceutical companies are entering precompetitive collaborations in order to address shared bottlenecks in biomedical research to spur...

  • More Funding Needed in Academia.  // Bioworld Week;9/8/2008, Vol. 16 Issue 36, p4 

    The article focuses on the insights of panelists on a workshop on funding translational medicine at the BioPharm America 2009 conference, citing that most drugs on the market are from biotechnology and pharmaceutical companies, though universities have spawned a large amount of research and...

  • Sharing pharma compounds with academia: experiences with providing vitamin D receptor ligands. Schmitz, Arndt A.; Hackethal, Sandra; Schulz, Anke; May, Ekkehard; Steinmeyer, Andreas; Z├╝gel, Ulrich; Asadullah, Khusru // Nature Reviews Drug Discovery;Apr2015, Vol. 14 Issue 4, p294 

    The article discusses a retrospective analysis of internal drug discovery efforts to target the vitamin D receptor (VDR). It relates the donation of compounds from pharmaceutical research groups to academic institutions. It details the results of a survey of 63 recipients who related their...

  • The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases. Coles, L D; Cloyd, J C // Clinical Pharmacology & Therapeutics;Aug2012, Vol. 92 Issue 2, p193 

    There are approximately 7,000 rare disorders, many of which are life-threatening. Diagnosis is often problematic, and therapies are few. Before the passage of the Orphan Drug Act in 1983, neither the pharmaceutical industry nor universities devoted much effort to research on rare diseases....

  • Designing Drugs for Parasitic Diseases of the Developing World. McKerrow, James H. // PLoS Medicine;Aug2005, Vol. 2 Issue 8, p712 

    Focuses on designing drugs for parasitic diseases of the developing world. Overview of several strategies for antiparasitic drug design, including an academic consortium that gets federal support for pharmacokinetic and toxicology studies; List of universities where a consortia modeled after...

  • Universities and FDA Collaborate to Reduce Cost of Manufacturing. Chiarello, Kaylynn // Pharmaceutical Technology;Nov2003, Vol. 27 Issue 11, p17 

    Reports on a collaborative research effort between the FDA, Georgetown University and Washington University in St. Louis, Missouri, aiming to tackle pharmaceutical manufacturing costs that will identify most efficient, low-cost ways to organize pharmaceutical manufacturing. Collaboration of...

  • U. of Mississippi plants seeds of in-state drug industry. Tarlach, Gemma M. // Drug Topics;2/16/98, Vol. 124 Issue 4, p92 

    Reports that the University of Mississippi's Research Institute of Pharmaceutical Sciences is developing a drug-development company. Function of the company; Discussion on the pharmaceutical industry in Mississippi; Comments from associate director of the National Center for Development of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics